• 1
    Morales A,Eidinger D,Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. 1976. J Urol.2002; 167(2 Pt 2): 891893; discussion 893–895.
  • 2
    Herr HW,Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol. 2008; 179: 5356.
  • 3
    Palou J,Laguna P,Millan-Rodriguez F,Hall RR,Salvador-Bayarri J,Vicente-Rodriguez J. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J Urol. 2001; 165: 14881491.
  • 4
    Hudson MA,Ratliff TL,Gillen DP,Haaff EO,Dresner SM,Catalona WJ. Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial. J Urol. 1987; 138: 295298.
  • 5
    Badalament RA,Herr HW,Wong GY, et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J Clin Oncol. 1987; 5: 441449.
  • 6
    Lamm DL,Blumenstein BA,Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000; 163(4): 11241129.
  • 7
    Sylvester RJ,van der Meijden AP,Witjes JA,Kurth K. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol. 2005; 174: 8691; discussion 91–92.
  • 8
    Martinez-Pineiro JA,Flores N,Isorna S, et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int. 2002; 89: 671680.
  • 9
    Colombel M,Saint F,Chopin D,Malavaud B,Nicolas L,Rischmann P. The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol. 2006; 176: 935939.